Utidelone

Generic Name: Utidelone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering. It is under investigation in clinical trials for various cancers.

Indication: 联合卡培他滨，用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer Patients with Brain Metastases

Interventions: Drug: Utidelone combined with Bevacizumab
Drug: Utidelone

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Target Recruit Count: 118

Registration Number: NCT06683703

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: utidelone
Drug: Cisplatin
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: RenJi Hospital

Target Recruit Count: 143

Registration Number: NCT06510465

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳
Renji Hospital, Shanghai, China

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Phase 2

Recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: UTD1

First Posted Date: 2024-04-26

Last Posted Date: 2024-04-26

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 53

Registration Number: NCT06385990

Locations: 🇨🇳
Quchang Ouyang, Changsha, Hunan, China

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Phase 2

Recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

Interventions: Drug: Utidelone
Drug: Tirelizumab
Drug: Bevacizumab

First Posted Date: 2023-11-09

Last Posted Date: 2023-11-09

Lead Sponsor: Huihua Xiong

Target Recruit Count: 78

Registration Number: NCT06125080

Locations: 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Organoid-guided treatment
Drug: Taxane
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Eribulin
Drug: Anthracycline
Drug: Carboplatin
Drug: Utidelone
Drug: Trastuzumab deruxtecan
Drug: Sacituzumab govitecan

First Posted Date: 2023-10-26

Last Posted Date: 2024-11-25

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 252

Registration Number: NCT06102824

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer
Neoadjuvant Therapy

Interventions: Drug: Utidelone
Drug: Carboplatin
Drug: Epirubicin
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 181

Registration Number: NCT05983094

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer
Breast Neoplasms

Interventions: Drug: utidelone
Drug: docetaxel

First Posted Date: 2022-06-24

Last Posted Date: 2023-07-13

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 349

Registration Number: NCT05430399

Locations: 🇨🇳
Shusen Wang, Guangzhou, Gangdong, China
🇨🇳
Hunan Cancer Hospital, Hunan, Hunan, China

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: utidelone

First Posted Date: 2022-06-03

Last Posted Date: 2022-06-03

Lead Sponsor: Fudan University

Target Recruit Count: 61

Registration Number: NCT05403333

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Phase 2

Conditions: Breast Cancer

Interventions: Drug: utidelone
Drug: Bevacizumab

First Posted Date: 2022-05-02

Last Posted Date: 2022-09-16

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05357417

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

Phase 2

Conditions: SCLC, Extensive Stage

Interventions: Drug: Utidelone
Drug: Placebo

First Posted Date: 2022-03-28

Last Posted Date: 2022-03-28

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05299255

Locations: 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy